Mechanistic insight of mitochondrial dysfunctions in cardiovascular diseases with potential biomarkers

다국어 초록 (Multilingual Abstract)

Background Acceleration of atherogenesis is an aftermath of cardiovascular diseases (CVDs), which arise with mitochondrial dysfunction (MD). Endothelium restraint inflammation, repair and fluidic exchange with nearby tissues. Endothelium-mediated mitochondrial damage can trigger the molecular mechanisms of vasodilation, pro-inflammation and process of pro-thrombotic accumulation in microvascular endothelial layer. The oxidation of lipid particles generates modified lipoproteins. Modification of mitochondrial function recently emerged a great concern towards the atherosclerosis initiation and progression, because the powerhouse of energy production mitochondria mutation can release mtDNA into cytoplasm and it can be act as sensor for viral DNA or foreign DNA. Another cause is mitochondrial imbalance can lead to product excess amount of reactive oxygen species (ROS) which can cause cellular metabolism and respiration system.


Objectives In previous some studies showed that mitochondrial dysfunction plays a vital role in term of cardiac diseases. However, very few studies provide evidence of endothelium-mediated mitochondrial imbalance. This study investigated the potential involvement of mitochondrial impairment in cardiotoxicity using a series of mechanistic endpoints, including mitochondrial respiration and endothelial suppression of inflammation, mitochondrial DNA. Our study provides some molecular mechanisms regarding mitochondrial role in endothelium function. In each section, we are trying to introduce key concepts and then analysis previous studies revealed the importance of that molecular mechanism regarding mitochondrial dysfunction.


Conclusions The ultimate goal of our review is to find out the novel drug discovery or new approaches of therapy. Our review will target different aspects of mitochondrial protein function and their effect of endothelial and cause of atherosclerosis diseases. To evaluate the healthy lifestyle and better condition of mitochondrial balance nowadays it is urgent to utilize the proper function for therapeutical effect for future direction.

다국어 초록 (Multilingual Abstract)

Background Acceleration of atherogenesis is an aftermath of cardiovascular diseases (CVDs), which arise with mitochondrial dysfunction (MD). Endothelium restraint inflammation, repair and fluidic exchange with nearby tissues. Endothelium-mediated mitochondrial damage can trigger the molecular mechanisms of vasodilation, pro-inflammation and process of pro-thrombotic accumulation in microvascular endothelial layer. The oxidation of lipid particles generates modified lipoproteins. Modification of mitochondrial function recently emerged a great concern towards the atherosclerosis initiation and progression, because the powerhouse of energy production mitochondria mutation can release mtDNA into cytoplasm and it can be act as sensor for viral DNA or foreign DNA. Another cause is mitochondrial imbalance can lead to product excess amount of reactive oxygen species (ROS) which can cause cellular metabolism and respiration system.




Objectives In previous some studies showed that mitochondrial dysfunction plays a vital role in term of cardiac diseases. However, very few studies provide evidence of endothelium-mediated mitochondrial imbalance. This study investigated the potential involvement of mitochondrial impairment in cardiotoxicity using a series of mechanistic endpoints, including mitochondrial respiration and endothelial suppression of inflammation, mitochondrial DNA. Our study provides some molecular mechanisms regarding mitochondrial role in endothelium function. In each section, we are trying to introduce key concepts and then analysis previous studies revealed the importance of that molecular mechanism regarding mitochondrial dysfunction.




Conclusions The ultimate goal of our review is to find out the novel drug discovery or new approaches of therapy. Our review will target different aspects of mitochondrial protein function and their effect of endothelial and cause of atherosclerosis diseases. To evaluate the healthy lifestyle and better condition of mitochondrial balance nowadays it is urgent to utilize the proper function for therapeutical effect for future direction.

참고문헌 (Reference)

• 1 James DI, "hFis1, a novel component of the mammalian mitochondrial fi ssion machinery" 278 (278): 36373-36379, 2003
• 2 Benitez S, "Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array" 1761 (1761): 1014-1021, 2006
• 3 Touyz RM, "Vascular Nox4 : a multifarious NADPH oxidase" 110 (110): 1159-1161, 2012
• 4 Xie Z, "Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes" 57 (57): 3222-3230, 2008
• 5 Kok BP, "Unlike two peas in a pod : lipid phosphate phosphatases and phosphatidate phosphatases" 112 (112): 5121-5146, 2012
• 6 Xia N, "Uncoupling of endothelial nitric oxide synthase in perivascular adipose tissue of diet-induced obese mice" 36 (36): 78-85, 2016
• 7 Okabe Y, "Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation" 202 (202): 1333-1339, 2005
• 8 Kopsidas G, "Tissue mitochondrial DNA changes. A stochastic system" 908 : 226-243, 2000
• 9 Karnovsky MJ, "The ultrastructural basis of capillary permeability studied with peroxidase as a tracer" 35 (35): 213-236, 1967
• 10 Pickrell AM, "The roles of PINK1, parkin, and mitochondrial fi delity in Parkinson’s disease" 85 (85): 257-273, 2015
• 11 Ferrari R, "The role of mitochondria in ischemic heart disease" 28 (28): S1-10, 1996
• 12 Poznyak AV, "The role of mitochondria in cardiovascular diseases" 9 (9): 137-, 2020
• 13 Wang C, "The role of mitochondria in apoptosis*" 43 : 95-118, 2009
• 14 Manderson AP, "The role of complement in the development of systemic lupus erythematosus" 22 : 431-456, 2004
• 15 Mallat Z, "The role of adaptive T cell immunity in atherosclerosis" 50 : 2009
• 16 Atkins K, "The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fi ssion : implications for human disease" 130 (130): 1861-1874, 2016
• 17 de Grey AD, "The reductive hotspot hypothesis of mammalian aging : membrane metabolism magnifi es mutant mitochondrial mischief" 269 (269): 2003-2009, 2002
• 18 Witztum JL, "The oxidative modifi cation hypothesis of atherosclerosis: does it hold for humans?" 11 (11): 93-102, 2001
• 19 Yoon Y, "The mitochondrial protein hFis1 regulates mitochondrial fi ssion in mammalian cells through an interaction with the dynamin-like protein DLP1" 23 (23): 5409-5420, 2003
• 20 Akar FG, "The mitochondrial origin of postischemic arrhythmias" 115 (115): 3527-3535, 2005
• 21 Koziel A, "The infl uence of high glucose on the aerobic metabolism of endothelial EA.hy926 cells" 464 (464): 657-669, 2012
• 22 Daniele G, "The infl ammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus" 51 (51): 123-131, 2014
• 23 Liao Y, "The function of the mitochondrial calcium uniporter in neurodegenerative disorders" 18 (18): 248-, 2017
• 24 Marian AJ, "The enigma of genetics etiology of atherosclerosis in the post-GWAS era" 14 (14): 295-299, 2012
• 25 Tan KT, "The endothelium and platelets in cardiovascular disease : potential targets for therapeutic intervention" 2 (2): 169-178, 2004
• 26 Kaludercic N, "The dual function of reactive oxygen/nitrogen species in bioenergetics and cell death : the role of ATP synthase" 2016 : 3869610-, 2016
• 27 Seifert PS, "The complement system in atherosclerosis" 73 (73): 91-10, 1988
• 28 Kuznetsov AV, "The cell-type specifi city of mitochondrial dynamics" 41 (41): 1928-1939, 2009
• 29 Giacomello M, "The cell biology of mitochondrial membrane dynamics" 21 (21): 204-224, 2020
• 30 Henne WM, "The assembly of lipid droplets and their roles in challenged cells" 2018
• 31 Ikegami Y, "The annual rate of coronary artery calcifi cation with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy" 4 : 7-, 2018
• 32 Saez-Atienzar S, "The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells : involvement of Drp-1-mediated mitochondrial fi ssion and mitochondrial-derived ROS signaling" 5 : e1368-, 2014
• 33 Steinberg D, "The LDL modifi cation hypothesis of atherogenesis:an update" 50 (50): S376-381, 2009
• 34 Hahn BH, "Systemic lupus erythematosus and accelerated atherosclerosis" 349 (349): 2379-2380, 2003
• 35 Taylor F, "Statins for the primary prevention of cardiovascular disease" 1 : CD004816-, 2011
• 36 Zhao H, "Sirt3inhibits cerebral ischemia-reperfusion injury through normalizing Wnt/beta-catenin pathway and blocking mitochondrial fi ssion" 23 (23): 1079-1092, 2018
• 37 Koba S, "Signifi cance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases" 189 (189): 206-214, 2006
• 38 Hoogeboom D, "Should I stay or should I go : beta-catenin decides under stress" 1796 (1796): 63-74, 2009
• 39 Aon MA, "Sequential opening of mitochondrial ion channels as a function of glutathione redox thiol status" 282 (282): 21889-21900, 2007
• 40 Kelso GF, "Selective targeting of a redox-active ubiquinone to mitochondria within cells : antioxidant and antiapoptotic properties" 276 (276): 4588-4596, 2001
• 41 Horton JD, "SREBPs : activators of the complete program of cholesterol and fatty acid synthesis in the liver" 109 (109): 1125-1131, 2002
• 42 Kjekshus J, "Rosuvastatin in older patients with systolic heart failure" 357 (357): 2248-2261, 2007
• 43 Lee YJ, "Roles of the mammalian mitochondrial fi ssion and fusion mediators Fis1, Drp1, and Opa1 in apoptosis" 15 (15): 5001-5011, 2004
• 44 Cannon RO 3rd, "Role of nitric oxide in cardiovascular disease : focus on the endothelium" 44 (44): 809-1819, 1998
• 45 Gall JM, "Role of mitofusin 2 in the renal stress response" 7 (7): e31074-, 2012
• 46 Raggi P, "Role of infl ammation in the pathogenesis of atherosclerosis and therapeutic interventions" 276 : 98-108, 2018
• 47 Davignon J, "Role of endothelial dysfunction in atherosclerosis" 109 (109): III27-32, 2004
• 48 Sproston NR, "Role of C-reactive protein at sites of infl ammation and infection" 9 : 754-, 2018
• 49 Berbee JF, "Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic eff ect of atorvastatin, in APOE3-LeidenCETP mice" 24 (24): 1423-1430, 2013
• 50 Sharma N, "Regulation of pyruvate dehydrogenase activity and citric acid cycle intermediates during high cardiac power generation" 562 (562): 593-560, 2005
• 51 Paradkar PN, "Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2" 29 (29): 1007-1016, 2009
• 52 Ishihara N, "Regulation and physiologic functions of GTPases in mitochondrial fusion and fi ssion in mammals" 19 (19): 389-399, 2013
• 53 Hu CL, "Reduced expression of the ferroptosis inhibitor glutathione peroxidase-4 in multiple sclerosis and experimental autoimmune encephalomyelitis" 148 (148): 426-439, 2019
• 54 Talukder MA, "Reduced SERCA2a converts sub-lethal myocardial injury to infarction and aff ects postischemic functional recovery" 46 (46): 285-287, 2009
• 55 Munzel T, "Redox regulation of dihydrofolate reductase : friend or troublemaker?" 35 (35): 2261-2262, 2015
• 56 Ait-Oufella H, "Recent advances on the role of cytokines in atherosclerosis" 31 (31): 969-979, 2011
• 57 Yang Z, "Recent advances in understanding endothelial dysfunction in atherosclerosis" 4 (4): 53-65, 2006
• 58 Jornot L, "Reactive oxygen metabolites increase mitochondrial calcium in endothelial cells : implication of the Ca2+/Na+ exchanger" 112 (112): 1013-1102, 1999
• 59 Forner F, "Quantitative proteomic comparison of rat mitochondria from muscle, heart, and liver" 5 (5): 608-619, 2006
• 60 Karbowski M, "Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis" 164 (164): 493-499, 2004
• 61 Dirkx E, "Protein kinase D1 is essential for contraction-induced glucose uptake but is not involved in fatty acid uptake into cardiomyocytes" 287 (287): 5871-5881, 2012
• 62 Ayoub C, "Prognostic value of segment involvement score compared to other measures of coronary atherosclerosis by computed tomography : a systematic review and meta-analysis" 11 (11): 258-267, 2017
• 63 Benitez S, "Pro-infl ammatory action of LDL(-)on mononuclear cells is counteracted by increased IL10 production" 1771 (1771): 613-622, 2007
• 64 Zhang M, "Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults : A nationally representative survey of 163, 641 adults" 260 : 196-203, 2018
• 65 Roman MJ, "Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus" 349 (349): 2399-2406, 2003
• 66 Asanuma Y, "Premature coronary-artery atherosclerosis in systemic lupus erythematosus" 349 (349): 2407-2415, 2003
• 67 Wurzel J, "Premature coronary disease in systemic lupus" 350 (350): 1571-1575, 2004
• 68 Rhew EY, "Premature atherosclerotic disease in systemic lupus erythematosus–role of infl ammatory mechanisms" 5 (5): 101-105, 2006
• 69 Mattu A, "Premature atherosclerosis and acute coronary syndrome in systemic lupus erythematosus" 23 (23): 696-703, 2005
• 70 Ahmed T, "Polysaccharides polymers for glaucoma treatment-a review" 2023
• 71 Dedonder-Decoopman E, "Plasma levels of VLDL-+ LDL-cholesterol, HDL-cholesterol, triglycerides and apoproteins B and A-I in a healthy population–infl uence of several risk factors" 37 (37): 559-568, 1980
• 72 Petri M, "Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus" 348 (348): 1120-1124, 1996
• 73 Di Pietro N, "Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis" 84 : 1-7, 2016
• 74 Handschin C, "Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism" 27 (27): 728-735, 2006
• 75 Narendra D, "Parkin is recruited selectively to impaired mitochondria and promotes their autophagy" 183 (183): 795-803, 2008
• 76 Sliter DA, "Parkin and PINK1 mitigate STING-induced infl ammation" 561 (561): 258-262, 2018
• 77 Alonso R, "PCSK9 and lipoprotein(a)levels are two predictors of coronary artery calcifi cation in asymptomatic patients with familial hypercholesterolemia" 254 : 249-253, 2016
• 78 Shapiro MD, "PCSK9 and atherosclerosis-lipids and beyond" 24 (24): 462-472, 2017
• 79 Cominacini L, "Oxidized low density lipoprotein(ox-LDL)binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species" 275 (275): 12633-12638, 2000
• 80 Chen XP, "Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells : role of reactive oxygen species" 47 (47): 1-9, 2007
• 81 Nagy L, "Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma" 93 (93): 229-240, 1998
• 82 Zheng J, "Oxidized LDL causes endothelial apoptosis by inhibiting mitochondrial fusion and mitochondria autophagy" 8 : 600950-, 2020
• 83 Quinn MT, "Oxidatively modifi ed low density lipoproteins : a potential role in recruitment and retention of monocyte/macrophages during atherogenesis" 84 (84): 2995-2998, 1987
• 84 Lum H, "Oxidant stress and endothelial cell dysfunction" 280 (280): C719-741, 2001
• 85 Li D, "Ox-LDL induces apoptosis in human coronary artery endothelial cells : role of PKC, PTK, bcl-2, and Fas" 275 (275): H568-576, 1998
• 86 Chen L, "OPA1 mutation and late-onset cardiomyopathy : mitochondrial dysfunction and mtDNA instability" 1 (1): e003012-, 2012
• 87 Chawla A, "Nuclear receptors and lipid physiology : opening the X-fi les" 294 (294): 1866-1870, 2001
• 88 Nunez MT, "Noxious iron-calcium connections in neurodegeneration" 13 : 48-, 2019
• 89 Papapanagiotou A, "Novel infl ammatory markers in hyperlipidemia : clinical implications" 22 (22): 2727-2743, 2015
• 90 Shibu MA, "Novel anti-aging herbal formulation Jing Si displays pleiotropic eff ects against aging associated disorders" 146 : 112427-, 2022
• 91 Jin Y, "Novel Insights Into the NLRP 3 Infl ammasome in Atherosclerosis" 8 (8): e012219-, 2019
• 92 Puri R, "Non-HDL cholesterol and triglycerides : implications for coronary atheroma progression and clinical events" 36 (36): 2220-2228, 2016
• 93 Li H, "Nitric oxide in the pathogenesis of vascular disease" 190 (190): 244-254, 2000
• 94 Ikeda Y, "New insights into the role of mitochondrial dynamics and autophagy during oxidative stress and aging in the heart" 2014 : 210934-, 2014
• 95 Ishikita A, "Nanoparticle-mediated delivery of mitochondrial division inhibitor 1 to the myocardium protects the heart from ischemia-reperfusion injury through inhibition of mitochondria outer membrane permeabilization: a new therapeutic modality for acute myocardial infarction" 2016
• 96 von Muhlinen N, "NDP52, a novel autophagy receptor for ubiquitin-decorated cytosolic bacteria" 6 (6): 288-289, 2010
• 97 Ivanov S, "NDP52 : the missing link between ubiquitinated bacteria and autophagy" 10 (10): 1137-1139, 2009
• 98 Violi F, "NADPH oxidase-2 and atherothrombosis : insight from chronic granulomatous disease" 37 (37): 218-225, 2017
• 99 Terman A, "Myocyte aging and mitochondrial turnover" 39 (39): 701-705, 2004
• 100 Korkmaz C, "Myocardial infarction in young patients(< or =35 years of age)with systemic lupus erythematosus : a case report and clinical analysis of the literature" 16 (16): 289-297, 2007
• 101 Han CB, "Mutations of mitochondrial 12S rRNA in gastric carcinoma and their signifi cance" 11 (11): 31-35, 2005
• 102 Heidari MM, "Mutation analysis of the mitochondrial tRNA Genes in Iranian coronary atherosclerosis patients" 46 (46): 1379-1385, 2017
• 103 Fors Nieves CE, "Mortality in Systemic Lupus Erythematosus : an Updated Review" 18 (18): 21-, 2016
• 104 Goldstein JL, "Molecular medicine. The cholesterol quartet" 292 (292): 1310-1312, 2001
• 105 Pasceri V, "Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1induction in human endothelial cells by anti-atherosclerosis drugs" 103 (103): 2531-2534, 2001
• 106 Ma K, "Mitophagy, Mitochondrial Homeostasis, and Cell Fate" 8 : 467-, 2020
• 107 Chourasia AH, "Mitophagy and cancer" 3 : 4-, 2015
• 108 Filadi R, "Mitofusin 2 : from functions to disease" 9 (9): 330-, 2018
• 109 Fernyhough P, "Mitochondrial stress and the pathogenesis of diabetic neuropathy" 5 (5): 39-49, 2010
• 110 Kumar S, "Mitochondrial sirtuins and their relationships with metabolic disease and cancer" 22 (22): 1060-1077, 2015
• 111 Koziel R, "Mitochondrial respiratory chain complex I is inactivated by NADPH oxidase Nox4" 452 (452): 231-239, 2013
• 112 van der Windt GJ, "Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development" 36 (36): 68-78, 2012
• 113 Tahrir FG, "Mitochondrial quality control in cardiac cells : mechanisms and role in cardiac cell injury and disease" 234 (234): 8122-8133, 2019
• 114 Xie LL, "Mitochondrial network structure homeostasis and cell death" 109 (109): 3686-3694, 2018
• 115 Okamoto K, "Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes" 39 : 503-536, 2005
• 116 Ballinger SW, "Mitochondrial integrity and function in atherogenesis" 106 (106): 544-549, 2002
• 117 Meeusen S, "Mitochondrial fusion intermediates revealed in vitro" 305 (305): 1747-1752, 2004
• 118 Hall AR, "Mitochondrial fusion and fi ssion proteins : novel therapeutic targets for combating cardiovascular disease" 171 (171): 1890-1906, 2014
• 119 Benard G, "Mitochondrial fusion and division : regulation and role in cell viability" 20 (20): 365-374, 2009
• 120 Pangare M, "Mitochondrial function in vascular endothelial cell in diabetes" 48 (48): 1-26, 2012
• 121 Moreira OC, "Mitochondrial function and mitophagy in the elderly : eff ects of exercise" 2017 : 2012798-, 2017
• 122 Sheridan C, "Mitochondrial fi ssion/fusion dynamics and apoptosis" 10 (10): 640-648, 2010
• 123 Salabei JK, "Mitochondrial fi ssion induced by plateletderived growth factor regulates vascular smooth muscle cell bioenergetics and cell proliferation" 1 : 542-551, 2013
• 124 Liu YJ, "Mitochondrial fi ssion and fusion : a dynamic role in aging and potential target for age-related disease" 186 : 111212-, 2020
• 125 Bonnard C, "Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice" 118 (118): 789-800, 2008
• 126 Lee SJ, "Mitochondrial dysfunction induces formation of lipid droplets as a generalized response to stress" 2013 : 327167-, 2013
• 127 Manolis AS, "Mitochondrial dysfunction in cardiovascular disease : current status of translational research/clinical and therapeutic implications" 41 (41): 275-313, 2021
• 128 Doi K, "Mitochondrial dysfunction in cardiorenal syndrome" 25 (25): 200-207, 2016
• 129 Peng W, "Mitochondrial dysfunction in atherosclerosis" 38 (38): 597-606, 2019
• 130 van Opbergen CJM, "Mitochondrial dysfunction as substrate for arrhythmogenic cardiomyopathy : a search for new disease mechanisms" 10 : 1496-, 2019
• 131 Mantena SK, "Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol-and obesity-induced fatty liver diseases" 44 (44): 1259-1272, 2008
• 132 Bhatti JS, "Mitochondrial dysfunction and oxidative stress in metabolic disorders-A step towards mitochondria based therapeutic strategies" 1863 (1863): 1066-1077, 2017
• 133 Shemiakova T, "Mitochondrial dysfunction and DNA damage in the context of pathogenesis of atherosclerosis" 8 (8): 166-, 2020
• 134 Suarez-Rivero JM, "Mitochondrial dynamics in mitochondrial diseases" 5 (5): 5-, 2016
• 135 Buck MD, "Mitochondrial dynamics controls T cell fate through metabolic programming" 166 (166): 63-76, 2016
• 136 Marin-Garcia J, "Mitochondrial dynamics and cell death in heart failure" 21 (21): 123-136, 2016
• 137 Tilokani L, "Mitochondrial dynamics : overview of molecular mechanisms" 62 (62): 341-360, 2018
• 138 Gorman GS, "Mitochondrial diseases" 2 : 16080-, 2016
• 139 McKenzie M, "Mitochondrial disease : mutations and mechanisms" 29 (29): 589-600, 2004
• 140 Camara AK, "Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury" 2 : 13-, 2011
• 141 Marchi S, "Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death" 69 : 62-72, 2018
• 142 Oka T, "Mitochondrial DNA that escapes from autophagy causes infl ammation and heart failure" 485 (485): 251-255, 2012
• 143 Taylor RW, "Mitochondrial DNA mutations in human disease" 6 (6): 389-402, 2005
• 144 Yu E, "Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through eff ects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans" 128 (128): 702-712, 2013
• 145 Yu EP, "Mitochondrial DNA damage and atherosclerosis" 25 (25): 481-487, 2014
• 146 Tang X, "Mitochondria, endothelial cell function, and vascular diseases" 5 : 175-, 2014
• 147 Leaw B, "Mitochondria, bioenergetics and excitotoxicity : new therapeutic targets in perinatal brain injury" 11 : 199-, 2017
• 148 Wang K, "Mitochondria removal by autophagy" 7 (7): 297-300, 2011
• 149 Scheffl er IE, "Mitochondria make a come back" 49 (49): 3-26, 2001
• 150 Dromparis P, "Mitochondria in vascular health and disease" 75 : 95-126, 2013
• 151 Bugger H, "Mitochondria in the diabetic heart" 88 (88): 229-240, 2010
• 152 Duchen MR, "Mitochondria in health and disease : perspectives on a new mitochondrial biology" 25 (25): 365-451, 2004
• 153 Parsons MJ, "Mitochondria in cell death" 47 : 99-114, 2010
• 154 Green DR, "Mitochondria and the autophagy-infl ammation-cell death axis in organismal aging" 333 (333): 1109-1112, 2011
• 155 Siasos G, "Mitochondria and cardiovascular diseases-from pathophysiology to treatment" 6 (6): 256-, 2018
• 156 Vyas S, "Mitochondria and cancer" 166 (166): 555-566, 2016
• 157 Yoshida H, "Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages" 18 (18): 794-802, 1998
• 158 Granger DN, "Microvascular responses to cardiovascular risk factors" 17 (17): 192-205, 2010
• 159 Prentki M, "Metabolic signaling in fuel-induced insulin secretion" 18 (18): 162-185, 2013
• 160 Makowski L, "Metabolic profi ling of PPARalpha-/-mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation" 23 (23): 586-604, 2009
• 161 Kim JA, "Mechanisms underlying benefi cial health eff ects of tea catechins to improve insulin resistance and endothelial dysfunction" 8 (8): 82-88, 2008
• 162 van der Bliek AM, "Mechanisms of mitochondrial fi ssion and fusion" 5 (5): a011072-, 2013
• 163 Ylikallio E, "Mechanisms of mitochondrial diseases" 44 (44): 41-59, 2012
• 164 Boden G, "Mechanisms of fatty acid-induced inhibition of glucose uptake" 93 (93): 2438-2446, 1994
• 165 Garrido C, "Mechanisms of cytochrome c release from mitochondria" 13 (13): 1423-1433, 2006
• 166 Kahn SE, "Mechanisms linking obesity to insulin resistance and type 2 diabetes" 444 (444): 840-846, 2006
• 167 Umezu R, "Macrophage(Drp1)dynamin-related protein 1 accelerates intimal thickening after vascular injury" 40 (40): e214-e226, 2020
• 168 Tabas I, "Macrophage phenotype and function in diff erent stages of atherosclerosis" 118 (118): 653-667, 2016
• 169 Ogura S, "Lox-1 : the multifunctional receptor underlying cardiovascular dysfunction" 73 (73): 1993-1999, 2009
• 170 Andrews HE, "Lowdensity lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta" 327 (327): 237-239, 1987
• 171 Yasue H, "Low-grade infl ammation, thrombogenicity, and atherogenic lipid profi le in cigarette smokers" 70 (70): 8-13, 2006
• 172 Chen CH, "Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fi broblast growth factor 2 transcription" 107 (107): 2102-2108, 2003
• 173 Steinberg D, "Low density lipoprotein oxidation and its pathobiological signifi cance" 272 (272): 20963-20966, 1997
• 174 Saitoh T, "Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production" 456 (456): 264-268, 2008
• 175 Cohen RA, "Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries" 63 (63): 903-910, 1988
• 176 Petan T, "Lipid droplets in cancer : guardians of fat in a stressful world" 23 (23): 1941-, 2018
• 177 Welte MA, "Lipid droplet functions beyond energy storage" 1862 (1862): 1260-1127, 2017
• 178 Schwandt P, "Lifestyle, cardiovascular drugs and risk factors in younger and elder adults : the PEP family heart study" 1 (1): 56-61, 2010
• 179 Stojanovski D, "Levels of human Fis1 at the mitochondrial outer membrane regulate mitochondrial morphology" 117 (117): 1201-1210, 2004
• 180 Riccioni G, "Leukotrienes in atherosclerosis : new target insights and future therapy perspectives" 2009 : 737282-, 2009
• 181 Back M, "Leukotriene signaling in atherosclerosis and ischemia" 23 (23): 41-48, 2009
• 182 Sugimoto K, "LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells" 84 (84): 127-136, 2009
• 183 Chen M, "LOX-1, the receptor for oxidized low-density lipoprotein identifi ed from endothelial cells : implications in endothelial dysfunction and atherosclerosis" 95 (95): 89-100, 2002
• 184 Abe Y, "L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion" 192 (192): 56-66, 2007
• 185 Yang CY, "Isolation, characterization, and functional assessment of oxidatively modifi ed subfractions of circulating low-density lipoproteins" 23 (23): 1083-1090, 2003
• 186 Li D, "Intracellular signaling of LOX-1 in endothelial cell apoptosis" 104 (104): 566-568, 2009
• 187 Stancel N, "Interplay between CRP, Atherogenic LDL, and LOX-1and its potential role in the pathogenesis of atherosclerosis" 62 (62): 320-327, 2016
• 188 Lu WW, "Intermedin1-53attenuates abdominal aortic aneurysm by inhibiting oxidative stress" 36 (36): 2176-2190, 2016
• 189 Kandel-Kfi r M, "Interleukin-1alpha defi ciency attenuates endoplasmic reticulum stressinduced liver damage and CHOP expression in mice" 63 (63): 926-933, 2015
• 190 Lacy M, "Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis" 193 : 50-62, 2019
• 191 Yoshida H, "Inhibitory eff ect of tea fl avonoids on the ability of cells to oxidize low density lipoprotein" 58 (58): 1695-1703, 1999
• 192 Reddy PH, "Inhibitors of mitochondrial fi ssion as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction" 40 (40): 245-256, 2014
• 193 Qian S, "Inhibition of glucose-induced vascular endothelial growth factor expression by Salvia miltiorrhiza hydrophilic extract in human microvascular endothelial cells : evidence for mitochondrial oxidative stress" 137 (137): 985-991, 2011
• 194 Zheng Z, "Inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through a mitochondrial ROS pathway in vitro" 51 (51): 64-71, 2010
• 195 Libby P, "Inflammation in atherosclerosis" 420 (420): 868-874, 2002
• 196 Li B, "Inflammation : a novel therapeutic target/direction in atherosclerosis" 23 (23): 1216-1227, 2017
• 197 Tousoulis D, "Infl ammatory cytokines in atherosclerosis : current therapeutic approaches" 37 (37): 1723-1732, 2016
• 198 Kaptoge S, "Infl ammatory cytokines and risk of coronary heart disease : new prospective study and updated meta-analysis" 35 (35): 578-589, 2014
• 199 Hansson GK, "Infl ammation, atherosclerosis, and coronary artery disease" 352 (352): 1685-1695, 2005
• 200 Bertrand MJ, "Infl ammation and beyond : new directions and emerging drugs for treating atherosclerosis" 22 (22): 1-26, 2017
• 201 Guo H, "Infl ammasomes : mechanism of action, role in disease, and therapeutics" 21 (21): 677-687, 2015
• 202 Brehm A, "Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle" 55 (55): 136-140, 2006
• 203 Lobo JC, "Increased electronegative LDL and decreased antibodies against electronegative LDL levels correlate with infl ammatory markers and adhesion molecules in hemodialysed patients" 412 (412): 1788-1179, 2011
• 204 Hirowatari Y, "Increase of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatment" 11 : 111-, 2012
• 205 Springer MZ, "In brief : mitophagy : mechanisms and role in human disease" 240 (240): 253-255, 2016
• 206 Kubera M, "In animal models, psychosocial stress-induced(neuro)infl ammation, apoptosis and reduced neurogenesis are associated to the onset of depression" 35 (35): 744-759, 2011
• 207 Petersen KF, "Impaired mitochondrial activity in the insulin-resistant off spring of patients with type 2 diabetes" 350 (350): 664-671, 2004
• 208 Niccoli G, "Impact of electronegative low-density lipoprotein on angiographic coronary atherosclerotic burden" 223 (223): 166-170, 2012
• 209 Lin J, "Impact of MCP-1 in atherosclerosis" 20 (20): 4580-4588, 2014
• 210 Mishra VK, "Identifying the therapeutic signifi cance of mesenchymal stem cells" 9 (9): 1145-, 2020
• 211 Lin P, "Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK-3beta/beta-catenin signalling pathways" 465 (465): 548-555, 2015
• 212 Refai TM, "Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients" 21 (21): 457-461, 2002
• 213 Du XL, "Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation" 97 (97): 12222-12226, 2000
• 214 Dymkowska D, "Hyperglycaemia modifies energy metabolism and reactive oxygen species formation in endothelial cells in vitro" 542 : 7-13, 2014
• 215 Ballinger SW, "Hydrogen peroxide-and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells" 86 (86): 960-966, 2000
• 216 Rhoads JP, "How oxidized low-density lipoprotein activates inflammatory responses" 38 (38): 333-342, 2018
• 217 Murphy MP, "How mitochondria produce reactive oxygen species" 417 (417): 1-13, 2009
• 218 de Sousa IF, "High-fat but not normal-fat intake of extra virgin olive oil modulates the liver proteome of mice" 60 (60): 1375-1388, 2021
• 219 Knowlton AA, "Heart failure and mitochondrial dysfunction : the role of mitochondrial fi ssion/fusion abnormalities and new therapeutic strategies" 63 (63): 196-206, 2014
• 220 Go AS, "Heart disease and stroke statistics–2013 update : a report from the American Heart Association" 127 (127): e6-e245, 2013
• 221 Chung CP, "Genetic variation and coronary atherosclerosis in patients with systemic lupus erythematosus" 23 (23): 876-880, 2014
• 222 McNew JA, "GTP-dependent membrane fusion" 29 : 529-550, 2013
• 223 Chan DC, "Fusion and fi ssion : interlinked processes critical for mitochondrial health" 46 : 265-287, 2012
• 224 Bergman RN, "Free fatty acids and pathogenesis of type 2 diabetes mellitus" 11 (11): 351-356, 2000
• 225 Chu CS, "Four statin benefi t groups defi ned by the 2013 ACC/AHA new cholesterol guideline are characterized by increased plasma level of electronegative low-density lipoprotein" 32 (32): 667-675, 2016
• 226 Li D, "Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction" 41 (41): 1048-1055, 2003
• 227 Cui Y, "Expression modifi cation of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose : the role of reactive oxygen species in diabetic retinopathy" 83 (83): 807-816, 2006
• 228 Pieper GM, "Enhanced, unaltered and impaired nitric oxidemediated endothelium-dependent relaxation in experimental diabetes mellitus : importance of disease duration" 42 (42): 204-213, 1999
• 229 Benz DJ, "Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fi broblast expressing high levels of human 15-lipoxygenase" 270 (270): 5191-5197, 1995
• 230 McLeod DS, "Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid" 147 (147): 642-653, 1995
• 231 Favero G, "Endothelium and its alterations in cardiovascular diseases : life style intervention" 2014 : 801896-, 2014
• 232 Fishman AP, "Endothelium : a distributed organ of diverse capabilities" 401 : 1-8, 1982
• 233 Vita JA, "Endothelial function : a barometer for cardiovascular risk?" 106 (106): 640-642, 2002
• 234 Dhananjayan R, "Endothelial dysfunction in type 2 diabetes mellitus" 31 (31): 372-379, 2016
• 235 Mudau M, "Endothelial dysfunction : the early predictor of atherosclerosis" 23 (23): 222-231, 2012
• 236 Yau JW, "Endothelial cell control of thrombosis" 15 : 130-, 2015
• 237 Zha X, "Endoplasmic reticulum stress aggravates viral myocarditis by raising infl ammation through the IRE1-associated NF-kappaB pathway" 31 (31): 1032-1040, 2015
• 238 Ikeda Y, "Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress" 116 (116): 264-278, 2015
• 239 Steinberg HO, "Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation" 100 (100): 1230-1239, 1997
• 240 Sanchez-Quesada JL, "Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control" 39 (39): 1469-1476, 1996
• 241 De Castellarnau C, "Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells" 20 (20): 2281-2287, 2000
• 242 Kruszynska YT, "Eff ects of nonesterifi ed fatty acids on glucose metabolism after glucose ingestion" 46 (46): 1586-1593, 1997
• 243 Zhou H, "Eff ects of melatonin on fatty liver disease: the role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fi ssion, and mitophagy" 2018
• 244 Staehr P, "Eff ects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis" 52 (52): 260-267, 2003
• 245 Benitez S, "Eff ect of simvastatin in familial hypercholesterolemia on the affi nity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor" 93 (93): 414-420, 2004
• 246 Tavazzi L, "Eff ect of n-3 polyunsaturated fatty acids in patients with chronic heart failure(the GISSI-HF trial) : a randomised, double-blind, placebo-controlled trial" 372 (372): 1223-1230, 2008
• 247 Osipov RM, "Eff ect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion" 120 (120): S22-30, 2009
• 248 Sanchez-Quesada JL, "Eff ect of glycemic optimization on electronegative low-density lipoprotein in diabetes : relation to nonenzymatic glycosylation and oxidative modifi cation" 86 (86): 3243-3249, 2001
• 249 Tuttolomondo A, "Editorial : treatment of atherosclerosis as an infl ammatory disease" 18 (18): 4265-, 2012
• 250 Yoshida H, "Edaravone, a novel radical scavenger, inhibits oxidative modifi cation of lowdensity lipoprotein(LDL)and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase" 179 (179): 97-102, 2005
• 251 Rosenson RS, "Dysfunctional HDL and atherosclerotic cardiovascular disease" 13 (13): 48-60, 2016
• 252 Olzmann JA, "Dynamics and functions of lipid droplets" 20 (20): 137-155, 2019
• 253 Ziouzenkova O, "Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein" 278 (278): 39874-39881, 2003
• 254 Jin JY, "Drp1-dependent mitochondrial fi ssion in cardiovascular disease" 42 (42): 655-664, 2021
• 255 Zeleny M, "Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation" 41 (41): 11820-11823, 2002
• 256 Pasceri V, "Direct proinfl ammatory eff ect of C-reactive protein on human endothelial cells" 102 (102): 2165-2168, 2000
• 257 Chipuk JE, "Direct activation of Bax by p53mediates mitochondrial membrane permeabilization and apoptosis" 303 (303): 1010-1014, 2004
• 258 Hamblin M, "Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-isoprostaglandin F2alpha and oxidized glutathione" 13 (13): 884-892, 2007
• 259 Fu Z, "Dietary fl avonol epicatechin prevents the onset of type 1 diabetes in nonobese diabetic mice" 61 (61): 4303-4309, 2013
• 260 Chen M, "Diabetes enhances lectin-like oxidized LDL receptor-1(LOX-1)expression in the vascular endothelium : possible role of LOX-1 ligand and AGE" 287 (287): 962-968, 2001
• 261 Sanchez-Quesada JL, "Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects" 43 (43): 699-705, 2002
• 262 Jin Q, "DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fi ssion and Bnip3-related mitophagy via the JNK pathways" 14 : 576-587, 2018
• 263 Jana BA, "Cytosolic lipid excess-induced mitochondrial dysfunction is the cause or eff ect of high fat diet-induced skeletal muscle insulin resistance : a molecular insight" 46 (46): 957-963, 2019
• 264 Tedgui A, "Cytokines in atherosclerosis : pathogenic and regulatory pathways" 86 (86): 515-581, 2006
• 265 Ramji DP, "Cytokines in atherosclerosis : Key players in all stages of disease and promising therapeutic targets" 26 (26): 673-685, 2015
• 266 Kleemann R, "Cytokines and atherosclerosis : a comprehensive review of studies in mice" 79 (79): 360-376, 2008
• 267 Shenderov K, "Cutting edge : Endoplasmic reticulum stress licenses macrophages to produce mature IL-1beta in response to TLR4stimulation through a caspase-8-and TRIF-dependent pathway" 192 (192): 2029-2033, 2014
• 268 Valanti EK, "Current and emerging reconstituted HDL-apoA-I and HDL-apoE approaches to treat atherosclerosis" 8 (8): 34-, 2018
• 269 Gimbrone MA Jr, "Culture of vascular endothelium" 3 : 1-28, 1976
• 270 Reubold TF, "Crystal structure of the GTPase domain of rat dynamin 1" 102 (102): 13093-13098, 2005
• 271 Faelber K, "Crystal structure of nucleotide-free dynamin" 477 (477): 556-560, 2011
• 272 Krintus M, "Critical appraisal of infl ammatory markers in cardiovascular risk stratifi cation" 51 (51): 263-279, 2014
• 273 Zhu L, "Correlation between mitochondrial dysfunction, cardiovascular diseases, and traditional Chinese medicine" 2020 : 2902136-, 2020
• 274 Patti ME, "Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes : potential role of PGC1 and NRF1" 100 (100): 8466-8471, 2003
• 275 Santel A, "Control of mitochondrial morphology by a human mitofusin" 114 (114): 867-874, 2001
• 276 Lubrano V, "Consolidated and emerging infl ammatory markers in coronary artery disease" 5 (5): 21-32, 2015
• 277 Xu X, "Concentration-dependent diversifcation eff ects of free cholesterol loading on macrophage viability and polarization" 37 (37): 419-431, 2015
• 278 Tedesco F, "Complement-endothelial cell interactions : pathophysiological implications" 36 (36): 261-226, 1999
• 279 Tedesco F, "Complement-endothelial cell interactions : pathophysiological implications" 37 (37): 9-, 2000
• 280 Inoue T, "Clinical signifi cance of the antibody against oxidized low-density lipoprotein in acute myocardial infarction" 98 (98): 13-11, 2002
• 281 Stalenhoef AF, "Clinical signifi cance of current perspectives in cholesterol metabolism" 130 (130): 951-955, 1986
• 282 Satoh M, "Cellular and molecular mechanisms of statins : an update on pleiotropic eff ects" 129 (129): 93-105, 2015
• 283 Stannard AK, "Cell-derived apolipoprotein E(ApoE)particles inhibit vascular cell adhesion molecule-1(VCAM-1)expression in human endothelial cells" 276 (276): 46011-46016, 2001
• 284 Danial NN, "Cell death : critical control points" 116 (116): 205-219, 2004
• 285 Nuttall SL, "Cardiovascular risk in systemic lupus erythematosus–evidence of increased oxidative stress and dyslipidaemia" 42 (42): 758-762, 2003
• 286 Brown DA, "Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization" 48 (48): 673-679, 2010
• 287 Missiroli S, "Cancer metabolism and mitochondria : fi nding novel mechanisms to fi ght tumours" 59 : 102943-, 2020
• 288 Willy JA, "CHOP links endoplasmic reticulum stress to NF-kappaB activation in the pathogenesis of nonalcoholic steatohepatitis" 26 (26): 2190-2204, 2015
• 289 Labrousse AM, "C. elegans dynamin-related protein DRP-1 controls severing of the mitochondrial outer membrane" 4 (4): 815-826, 1999
• 290 Bhatt MP, "C-peptide activates AMPKalpha and prevents ROS-mediated mitochondrial fi ssion and endothelial apoptosis in diabetes" 62 (62): 3851-3862, 2013
• 291 Bengsch B, "Bioenergetic insuffi ciencies due to metabolic alterations regulated by the inhibitory receptor PD-1are an early driver of CD8(+)T Cell Exhaustion" 45 (45): 358-373, 2016
• 292 Zhou H, "BI1 is associated with microvascular protection in cardiac ischemia reperfusion injury via repressing Syk-Nox2-Drp1-mitochondrial fi ssion pathways" 21 (21): 599-615, 2018
• 293 Bosc C, "Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites" 11 (11): 4056-, 2020
• 294 Kundu M, "Autophagy : basic principles and relevance to disease" 3 : 427-455, 2008
• 295 Tsokos GC, "Autoimmunity, complement activation, tissue injury and reciprocal eff ects" 7 : 149-164, 2004
• 296 Ross R, "Atherosclerosis–an infl ammatory disease" 340 (340): 115-126, 1999
• 297 Ross R, "Atherosclerosis is an infl ammatory disease" 138 (138): S419-420, 1999
• 298 Ruiz-Limon P, "Atherosclerosis and cardiovascular disease in systemic lupus erythematosus : eff ects of in vivo statin treatment" 74 (74): 1450-1458, 2015
• 299 Carmena R, "Atherogenic lipoprotein particles in atherosclerosis" 109 (109): 2-7, 2004
• 300 Steinberg D, "Atherogenesis in perspective : hypercholesterolemia and inflammation as partners in crime" 8 (8): 1211-1217, 2002
• 301 Higashi Y, "Assessment of endothelial function. History, methodological aspects, and clinical perspectives" 56 (56): 125-134, 2015
• 302 Anderson TJ, "Assessment and treatment of endothelial dysfunction in humans" 34 (34): 631-638, 1999
• 303 Chang PY, "Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism : a novel cytoprotective role of aspirin in acute myocardial infarction" 99 (99): 137-145, 2013
• 304 Wu D, "Apolipoprotein E-defi cient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophages" 48 (48): 2571-2578, 2007
• 305 Yue L, "Apolipoprotein E enhances endothelial-NO production by modulating caveolin 1 interaction with endothelial NO synthase" 60 (60): 1040-1046, 2012
• 306 Mahley RW, "Apolipoprotein E : cholesterol transport protein with expanding role in cell biology" 240 (240): 622-630, 1988
• 307 Charo IF, "Anti-infl ammatory therapeutics for the treatment of atherosclerosis" 10 (10): 365-376, 2011
• 308 Ippolito A, "An update on mortality in systemic lupus erythematosus" 26 (26): S72-79, 2008
• 309 Sawamura T, "An endothelial receptor for oxidized low-density lipoprotein" 386 (386): 73-77, 1997
• 310 Simoneau JA, "Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM" 83 (83): 166-171, 1997
• 311 Pouwer MG, "Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice" 61 (61): 365-375, 2020
• 312 Kuhnast S, "Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the eff ects of a statin" 55 (55): 2103-2112, 2014
• 313 Sanda GM, "Aggregated LDL turn human macrophages into foam cells and induce mitochondrial dysfunction without triggering oxidative or endoplasmic reticulum stress" 16 (16): e0245797-, 2021
• 314 Berg AH, "Adipose tissue, infl ammation, and cardiovascular disease" 96 (96): 939-949, 2005
• 315 Currie B, "Acute myocardial infarction in a young Papuan woman with systemic lupus erythematosus" 32 (32): 181-184, 1989
• 316 Denk A, "Activation of NF-kappa B via the Ikappa B kinase complex is both essential and suffi cient for proinfl ammatory gene expression in primary endothelial cells" 276 (276): 28451-28458, 2001
• 317 Skaggs BJ, "Accelerated atherosclerosis in patients with SLE–mechanisms and management" 8 (8): 214-223, 2012
• 318 Beer M, "Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with(31)P-SLOOP magnetic resonance spectroscopy" 40 (40): 1267-1274, 2002
• 319 Dose J, "APOE genotype and stress response-a mini review" 15 : 121-, 2016
• 320 Parthasarathy S, "A role for endothelial cell lipoxygenase in the oxidative modifi cation of low density lipoprotein" 86 (86): 1046-1050, 1989
• 321 Wadhera RK, "A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality" 10 (10): 472-489, 2016
• 322 Brown MS, "A receptor-mediated pathway for cholesterol homeostasis" 232 (232): 34-47, 1986
• 323 de Grey AD, "A proposed refi nement of the mitochondrial free radical theory of aging" 19 (19): 161-166, 1997
• 324 Dai L, "A modifi ed form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fl uid" 22 (22): 705-710, 1997
• 325 Sparks LM, "A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle" 54 (54): 1926-1933, 2005
• 326 Yuan Hsieh DJ, "A combination of isoliquiritigenin with Artemisia argyi and Ohwia caudata water extracts attenuates oxidative stress, infl ammation, and apoptosis by modulating Nrf2/Ho-1 signaling pathways in SD rats with doxorubicin-induced acute cardiotoxicity" 38 (38): 3026-3042, 2023
• 327 Stone NJ, "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines" 129 (129): S1-45, 2014
• 328 Goff DC Jr, "2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines" 129 (129): S49-73, 2014
• 329 Goff DC Jr, "2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines" 63 (63): 2935-2959, 2014
• 330 Greenland P, "2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines" 56 (56): e50-103, 2010